<DOC>
	<DOCNO>NCT01799473</DOCNO>
	<brief_summary>This prospective , observational , multi-center , patient registry follow patient newly initiate Tyvaso treatment Pulmonary Arterial Hypertension ( PAH ) . Once enrolled , patient ' dose titration follow first 6 month treatment Tyvaso . A call-center contact patient directly week 1 , 2 , 3 , 4 , 8 , 12 , 16 , 20 , 24 review dose titration schedule . In addition patient-reported dosing data , patient demographic information , collect investigative site Baseline .</brief_summary>
	<brief_title>Tyvaso Dosing Titration Evaluation : TyTRATE Registry</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Are newly prescribe Tyvaso treatment PAH plan initiate therapy Are willing able contact patient call center . Have previously receive Tyvaso . Are currently enrol interventional ( nonFDA approve ) PH clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Tyvaso</keyword>
	<keyword>PAH</keyword>
</DOC>